A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NCT07743190 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC)
Elevated Tumor-Infiltrating Lymphocytes

Interventions

DRUG: Carboplatin
DRUG: Paclitaxcel
DRUG: Pembrolizumab

Sponsor

Medical University of South Carolina

Collaborators

[object Object]